Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.2 to 2.10.3, indicating a new release.
    Difference
    0.1%
    Check dated 2024-09-04T04:23:02.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.
    Difference
    0.1%
    Check dated 2024-08-13T22:57:09.000Z thumbnail image
  5. Check
    35 days ago
    No Change Detected
  6. Check
    50 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0 and now includes 3 locations, replacing the previous version v2.9.7.
    Difference
    0.3%
    Check dated 2024-07-23T14:19:03.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:14:16.000Z thumbnail image
  8. Check
    71 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T14:18:17.000Z thumbnail image
  9. Check
    76 days ago
    Change Detected
    Summary
    The value of Revision has changed from v2.9.3 to v2.9.5, indicating an update or modification to the content of the web page.
    Difference
    0.1%
    Check dated 2024-06-27T10:05:19.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.